Table 1.
Basic characteristics, clinical manifestation, and auxiliary examination results of patients with MS or NMOSD in this study
| Variables | MS (n = 85) | NMOSD (n = 90) | Statistics | P |
|---|---|---|---|---|
| Gender, male/female | 30/55 | 21/69 | 3.00* | 0.08 |
| Age (years), median (IQR) | 34 (21) | 41 (25) | −1.17† | 0.24 |
| Age at onset (years), median (IQR) | 32 (20) | 36 (24) | −1.29† | 0.20 |
| EDSS at last visit, median (IQR) | 2 (2) | 3.5 (3) | −3.69† | <0.01 |
| Autoimmune disease frequency, n (%) | 5 (6) | 17 (19) | 6.90* | <0.01 |
| MRI findings, n (%) | ||||
| Midbrain lesions frequency | 16 (20) | 6 (7) | 6.90* | <0.01 |
| Pontine lesions frequency | 39 (49) | 22 (25) | 11.00* | <0.01 |
| Medulla lesions frequency | 18 (23) | 24 (27) | 0.39* | 0.53 |
| Periventricular lesions frequency | 52 (66) | 20 (22) | 32.10* | <0.01 |
| Juxtacortical frequency | 29 (37) | 8 (9) | 18.70* | <0.01 |
| Infratentorial lesions frequency | 14 (18) | 3 (3) | 9.50* | <0.01 |
| Long-cord lesions (>3 VS) frequency | 19 (21) | 14 (61) | 14.70* | <0.01 |
| CSF analysis | ||||
| CSF-WBC count (×106/L), median (IQR) | 5 (8) | 5 (8) | 0.46† | 0.64 |
| CSF protein (mg/L), median (IQR) | 320 (290) | 360 (310) | 1.67† | 0.10 |
| AQP4-Ab CSF positive frequency, n (%) | 0 | 30 (46) | 36.40* | <0.01 |
| CSF-SOB frequency, n (%) | 46 (59) | 16 (20) | 25.70* | <0.01 |
| CSF-MBP frequency, n (%) | 9 (19) | 16 (42) | 5.90* | 0.02 |
| CSF-MOG-Ab (IQR) | 0.45 (0.34) | 0.33 (0.51) | 0.37† | 0.72 |
| Serum analysis | ||||
| AQP4-Ab seropositive frequency, n (%) | 0 | 47 (67) | 63.90* | <0.01 |
| Serum MOG-Ab (IQR) | 0.72 (0.81) | 0.47 (0.47) | 2.04† | 0.04 |
*χ2 values; †Z values. MS: Multiple sclerosis; NMOSD: Neuromyelitis optica spectrum disease; IQR: Interquartile range; EDSS: Expanded Disability Status Scale; VS: Vertebral segments; CSF: Cerebrospinal fluid; WBC: White blood cell; AQP4-Ab: Aquaporin-4-antibody; SOB: Specific oligoclonal bands; MBP: Myelin basic protein; MOG-Ab: Myelin oligodendrocyte glycoprotein antibody.